Sustained release tablet formulation to treat Parkinson's disease
The sustained release tablet of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) which is disclosed permits twice daily administration of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (
-
(2008/06/13)
Heterocyclic amines having central nervous system activity
Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula: STR1 and pharmaceutically acceptable salts thereof wherein R1 and R2 are
-
(2008/06/13)
Synthesis of the Selective D2 Receptor Agonist PNU-95666E from D-Phenylalanine Using a Sequential Oxidative Cyclization Strategy
Compound 1 (PNU-95666E) is a selective and high-affinity agonist at the dopamine D2 receptor subtype and is of interest as a potential agent for the treatment of Parkinson's disease. Requiring a synthetic route amenable to scale-up, a synthesis
Romero, Arthur G.,Darlington, William H.,McMillan, Moses W.
p. 6582 - 6587
(2007/10/03)
More Articles about upstream products of 166742-96-7